SOL-GEL TECHNOLOGIES LTD

Opaleye Management’s new stake in SOL‑GEL boosts its share from 15% to 16.4%, backing the firm’s growing dermatology pipeline and value‑based reimbursement strategy.

Opaleye Management’s latest $73.69 buy of 300 SOL‑GEL shares signals steady institutional backing for the high‑growth pharma stock, hinting at future pipeline strength.

Opaleye’s steady buying of Sol‑Gel Technologies shares signals confidence in its dermatology pipeline, suggesting potential upside amid volatile biotech markets.